S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

$7.30
-0.11 (-1.48%)
(As of 03/28/2024 ET)
Today's Range
$7.25
$7.59
50-Day Range
$7.30
$9.74
52-Week Range
$3.16
$10.13
Volume
6.72 million shs
Average Volume
5.55 million shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.36

Ardelyx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
69.3% Upside
$12.36 Price Target
Short Interest
Bearish
15.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
0.40mentions of Ardelyx in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to $0.08 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

141st out of 939 stocks

Pharmaceutical Preparations Industry

60th out of 444 stocks

ARDX stock logo

About Ardelyx Stock (NASDAQ:ARDX)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Stock Price History

ARDX Stock News Headlines

Ardelyx, Inc. Reports Employment Inducement Grants
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
ARDX Apr 2024 7.500 put
ARDX Apr 2024 10.000 call
The ProTrader Dashboard is simple to use! (trade demo inside)
Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.
Ardelyx Inc
Short Interest in Ardelyx, Inc. (NASDAQ:ARDX) Expands By 11.8%
Guru Fundamental Report for ARDX
ARDX Mar 2024 11.000 call
ARDX Mar 2024 8.000 put
ARDX Mar 2024 8.000 call
ARDX Mar 2024 8.500 call
ARDX Mar 2024 10.000 put
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Ardelyx, Inc. Reports Employment Inducement Grants
ARDX Mar 2024 12.000 call
ARDX Mar 2024 7.500 put
ARDX Mar 2024 7.500 call
Stocks on the Launchpad: The Next 3 Market Sensations
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/29/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARDX
Employees
267
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$12.36
High Stock Price Target
$15.00
Low Stock Price Target
$8.50
Potential Upside/Downside
+69.3%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-66,070,000.00
Pretax Margin
-52.65%

Debt

Sales & Book Value

Annual Sales
$124.46 million
Book Value
$0.72 per share

Miscellaneous

Free Float
219,888,000
Market Cap
$1.70 billion
Optionable
Optionable
Beta
0.88

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

ARDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price target for 2024?

7 Wall Street research analysts have issued 1 year target prices for Ardelyx's shares. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's stock price to reach $12.36 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2024?

Ardelyx's stock was trading at $6.20 at the start of the year. Since then, ARDX shares have increased by 17.7% and is now trading at $7.30.
View the best growth stocks for 2024 here
.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in March. As of March 15th, there was short interest totaling 36,310,000 shares, an increase of 8.0% from the February 29th total of 33,610,000 shares. Based on an average daily volume of 6,230,000 shares, the days-to-cover ratio is currently 5.8 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $34.36 million during the quarter, compared to the consensus estimate of $34.26 million. Ardelyx had a negative trailing twelve-month return on equity of 43.57% and a negative net margin of 53.08%. The business's revenue for the quarter was down 22.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.06 EPS.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.61%), Vanguard Group Inc. (5.60%), Eventide Asset Management LLC (2.93%), Rubric Capital Management LP (1.73%), Price T Rowe Associates Inc. MD (1.00%) and Price T Rowe Associates Inc. MD (1.00%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners